dcsimg
Intended for Healthcare Professionals OnlyIntended for US Audiences

Proven Clinical Experience

Only ADVATE® [Antihemophilic Factor (Recombinant)] has 13 years of experience in the real world as a third-generation plasma/albumin-free recombinant factor VIII8

  • Extensively studied with evidence spanning over a decade from 12 prospective studies2-7
  • Most widely used* with more than 25 billion IUs distributed worldwide9
  • Proven record of clinical performance2-7
  • Third-generation full-length molecule similar to the factor VIII that occurs naturally in the body1,8

*Based on units sold as of July 2016.

Efficacy

ADVATE prophylaxis may help your patients prevent or reduce the frequency of bleeds1

See data

Established Safety Profile

Learn about safety findings from the ADVATE clinical trials.

See the results